Navigation Links
Rafarma Pharmaceuticals, Inc. Receives General License for Pharmaceutical Products and has Started to Manufacture 3 New Products
Date:2/4/2013

SANDY, Utah, Feb. 4, 2013 /PRNewswire/ -- Rafarma Pharmaceuticals, Inc. (the "Company") OTC symbol (RAFA) announced that it has received the general license for pharmaceutical products and has started the manufacturing of 3 new products.  The general license was one of the final steps required to open the new plant in Terbuniy.  The Company is now in operation and is expected to rapidly increase to 100% capacity of the Terbiniy facility with the addition of government contracts provided by being 1 of 4 National Strategic Pharmaceutical Suppliers to the Russian Federation.

The new products are Sodium Para-Aminosalicilate, Ibuprofen, and Betagistin.  Sodium Para-Aminosalicilate is a tablet with a time release cover. The current dosage manufactured is 1000 mg and is designed to be of use against various forms of tuberculosis. Sodium Para-Aminosalicilate can also be used in conjunction with other anti-tuberculosis medications.  The Ibuprofen manufactured is Rectal Suppositories for children and the currently manufactured dosage is 60 mg.  Betagistin Tablets are manufactured in dosages of 8 mg, 16 mg and 24 mg. The product is used to treat Manier Syndrome which is characterized by drowsiness, nausea, reduction in hearing abilities and noise in the ears. It is also used as treatment of vestibular vertigo.

Julia Andrushkova, a company spokesperson, was quoted as saying:  "Receiving the general license for pharmaceutical products has been a major step to success for the many people involved, and for the Company in general."

Safe Harbor Statement 
Matters discussed in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in this press release, the words "anticipate," "believe," "estimate,"  "may," "intend," "expect" and similar expressions identify such forward-looking statements. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein. These forward-looking statements are based largely on the expectations of the Company and are subject to a number of risks and uncertainties. These include, but are not limited to: the impact of economic, competitive and other factors affecting the Company and its operations, markets, product, and distributor performance.


'/>"/>
SOURCE Rafarma Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Rafarma Pharmaceuticals, Inc. Named 1 Of 4 National Strategic Pharmaceutical Suppliers To The Russian Federation
2. Auxilium Pharmaceuticals, Inc. Announces Issuance of $350.0 Million of 1.50% Convertible Senior Notes Due 2018
3. Auxilium Pharmaceuticals, Inc. Announces Pricing of $325.0 Million of 1.50% Convertible Senior Notes Due 2018
4. Ryan & Maniskas, LLP Announces Investigation of MAP Pharmaceuticals, Inc.
5. Harwood Feffer LLP Announces Investigation of MAP Pharmaceuticals, Inc.
6. Watson Pharmaceuticals, Inc. is Now Actavis, Inc.
7. Auxilium Pharmaceuticals, Inc. Announces Offering of Convertible Senior Notes Due 2018
8. SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of MAP Pharmaceuticals, Inc. - MAPP
9. Building on a Legacy: Vinita Gupta, CEO of Lupin Pharmaceuticals, Inc., Named Ernst & Young U.S. 2012 Family Business Award of Excellence winner
10. Ground Zero Pharmaceuticals, Inc. (GZP) Announces Enhanced Biosimilars and Personalized Medicine Initiatives for its Clients
11. Achillion Pharmaceuticals, Inc. Hosts the HCV Connection Media Briefing at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... Mylan N.V. (NASDAQ, TASE: MYL) today announced ... December 31, 2015. --> --> ... revenues of $9.45 billion, up 28% on a constant ... of $9.43 billion. Excluding the impact of the acquisition ... generics business (the "EPD Business"), full year adjusted total ...
(Date:2/10/2016)... , Feb. 10, 2016  Resolve Therapeutics, LLC, ... new approaches to the treatment of lupus and ... a multiple ascending dose study in patients with ... RSLV-132. --> --> ... multiple ascending dose study of RSLV-132 in 32 ...
(Date:2/10/2016)... , Feb. 10, 2016  Rich Pharmaceuticals, Inc. (OTC ... a 1-for-100 reverse split of its issued and outstanding ... trading on Thursday, February 11, 2016. The Company,s common ... CUSIP number 76303T308 and temporary ticker symbol "RCHAD". After ... under the ticker symbol (RCHA).  --> ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... February 10, 2016 , ... Western University ... health services to the developmentally disabled in the Coachella Valley. , The two ... new facility at 71-949 Highway 111, Suite 100-B, in Rancho Mirage, California. The ...
(Date:2/10/2016)... ... February 10, 2016 , ... As part of its ongoing ... February 2016. Each webinar features a dynamic expert and thoughtful presentation to give ... patients and facilities. Both events are free to attend, but registration is ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... American Academy of Emergency Medicine , an emergency medicine professional association, ... practice management services . , The American Academy of Emergency Medicine, or AAEM, ...
(Date:2/10/2016)... ... 2016 , ... The Wickman Agency in Garland, TX has ... community. Pledging to select a new beneficiary every 60 days, the agency will ... is to bring community awareness to important local causes by forming campaigns which ...
(Date:2/10/2016)... ... February 10, 2016 , ... 10 Best Water ... were three leading bottled water brand owners that topped the list as a result ... and optimize conversion. The premier brand was Tibet 5100, a top notch water company ...
Breaking Medicine News(10 mins):